Table V.
Comparison of laboratory parameters and clinical characteristics between essential thrombocythemia patients stratified by their mutation status of CALR, JAK2 and MPL.
| Parameter/characteristic | Group A TN (n=28) | Group B CALR-mutant (n=23) | Group C JAK2 V617F-mutant (n=21) | Total P-value | P-value (A vs. B) | P-value (A vs. C) | P-value (B vs. C) |
|---|---|---|---|---|---|---|---|
| Age at diagnosis (years) | 55; | 52; | 66; | 0.002 | 0.585 | 0.002 | 0.008 |
| 51.14±12.56 | 52.96±10.61 | 64.76±16.99 | |||||
| Female | 16 (57.1) | 13 (56.5) | 11 (52.4) | 0.940 | 0.964 | 0.740 | 0.783 |
| ASXL1 mutations | 4 (14.3) | 5 (21.7) | 5 (23.8) | 0.751 | 0.745 | 0.632 | 1.000 |
| WBC count, ×109/l | 8.70; | 8.38; | 10.59; | 0.010 | 0.457 | 0.02 | 0.066 |
| 8.20±2.17 | 8.82±3.73 | 12.40±7.80 | |||||
| Hemoglobin, g/l | 138.50; | 130.00; | 131.30; | 0.361 | 0.074 | 0.885 | 0.349 |
| 140.37±22.41 | 129.29±20.48 | 138.90±41.88 | |||||
| Platelet count, ×109/l | 672.00; | 785.00; | 485.00; | 0.105 | 0.381 | 0.171 | 0.047 |
| 706.79±324.49 | 787.91±327.94 | 562.17±403.82 | |||||
| Signs/symptoms | |||||||
| Bleeding | 2 (7.1) | 1 (4.3) | 1 (4.8) | 1.000 | 1.000 | 1.000 | 1.000 |
| Dizziness, palpitation, chest congestion | 4 (14.3) | 9 (39.1) | 8 (38.1) | 0.086 | 0.043 | 0.050 | 0.944 |
| Numbness | 0 (0) | 3 (13.0) | 4 (19.0) | 0.038 | 0.170 | 0.060 | 0.896 |
| Feebleness | 3 (10.7) | 3 (13.0) | 4 (19.0) | 0.699 | 1.000 | 0.680 | 0.896 |
| Splenomegaly/hepatomegaly Previous history | 3 (10.7) | 2 (8.7) | 6 (28.6) | 0.159 | 1.000 | 0.221 | 0.188 |
| Hypertension | 7 (25.0) | 2 (8.7) | 4 (19.0) | 0.295 | 0.250 | 0.882 | 0.576 |
| Coronary heart disease | 2 (7.1) | 3 (13.0) | 2 (9.5) | 0.882 | 0.817 | 1.000 | 1.000 |
Values are expressed as the ‘median; mean (standard deviation)’ or as ‘n (%)’. WBC, white blood cell; ASXL1, additional sex combs like 1; wt, wild-type; TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; MPL, myeloproliferative leukemia.